VERIDIANA PIRES DE CAMARGO
Índice h a partir de 2011
7
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
37 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 37
- Treatment of advanced melanoma - A changing landscape(2017) HEPNER, Adriana; SALGUES, Alessandra; ANJOS, Carlos A. dos; SAHADE, Marina; CAMARGO, Veridiana P.; GARICOCHEA, Bernardo; SHOUSHTARI, Alexander N.; POSTOW, Michael A.; FERNANDES, Gustavo S.; MUNHOZ, Rodrigo R.Following decades of relative ostracism, advances in the treatment of melanoma have brought a new reality for patients, physicians and researchers. While antibodies targeting molecules involved in the modulation of the interaction between melanoma and immune cells changed the meaning of the term ""cancer immunotherapy,"" a better characterization of the molecular aberrations involved in melanoma carcinogenesis prompted the development of inhibitors of the mitogen-activated protein kinase pathway (MAPK) that also led to significant improvements both in response rates and survival. As a result, new drugs have been approved for clinical use in the United States and Europe, including the immune-checkpoint blockers ipilmumab, pembrolizumab and nivolumab, the oncolytic herpesvirus talimogene laherparepvec, and the targeted-agents vemurafenib, dabrafenib, cobimetinib and trametinib. In this article, we review the results of studies that brought new approaches to the bedside and discuss how these developments are being incorporated into the care of patients in Brazil.
- Trends in Melanoma Mortality in Brazil: A Registry-Based Study(2020) MARTA, Guilherme Nader; MUNHOZ, Rodrigo Ramella; TEIXEIRA, Monica La Porte; WALDVOGEL, Bernadette Cunha; CAMARGO, Veridiana Pires de; FEHER, Olavo; SANCHES, Jose AntonioPURPOSE A substantial increase in melanoma incidence has been consistently observed worldwide over the past decades. However, melanoma mortality rates have remained stable or declined over the past years in most regions. Given the paucity of melanoma mortality data for different Brazilian regions, we sought to describe melanoma mortality trends in southeastern Brazil and their relationship with demographic variables. MATERIALS AND METHODS A cross-sectional registry-based analysis was conducted to describe melanoma mortality trends in the state of SAo Paulo, Brazil, from 1996 to 2016. Demographic information from melanoma-related death records, including sex and age, was collected from the FundacAo Sistema Estadual de Analise de Dados database. The annual percentage change (APC) was calculated to identify mortality trends over the period. RESULTS An increasing melanoma mortality trend was detected among males, regardless of age (APC, 1.72%; P < .001), and was more pronounced for men >= 60 years old (APC, 2.63%; P < .001). Melanoma mortality rates have also increased for patients >= 60 years old, regardless of sex (APC, 1.11%; P < .001). A non-statistically significant increase in the overall melanoma mortality rate was observed over the 20-year period analyzed (APC, 0.36%; P = .4). CONCLUSION Our data suggest a stable melanoma mortality over the past two decades for the overall population studied; however, a significant increase in melanoma mortality rates has been demonstrated among males and in the population >= 60 years old, emphasizing the need to implement prevention strategies and expand access to effective therapies for this population. (c) 2020 by American Society of Clinical Oncology
- Tolerability of modified gemcitabine/docetaxel (split-dose) in patients with advanced soft tissue sarcomas(2016) AZEVEDO, R. G. M. V. D.; FRAILE, N.; SAADI NETO, E.; LOPEZ, R. V. M.; TOLOI, D.; HOFF, P. M.; FEHER, O.; CAMARGO, V. P. D.; MUNHOZ, R.
bookPart Sarcomas: partes moles e ósseos(2016) CAMARGO, Veridiana Pires de- Trends in melanoma mortality in Brazil: A 20-year registry-based study(2020) MARTA, G. Nader; MUNHOZ, R. Ramella; TEIXEIRA, M. La Porte; WALDVOGEL, B. Cunha; CAMARGO, V. P. D.; NARDO, M.; BARBOSA, C. Chaul de Lima; FEHER, O.; HOFF, P. M.; SANCHES, J. A.
- Response to Paclitaxel in an Adult Patient with Advanced Kaposiform Hemangioendothelioma(2016) MOTA, Jose Mauricio; SCARANTI, Mariana; FONSECA, Leonardo G.; TOLOI, Diego Araujo; CAMARGO, Veridiana Pires de; MUNHOZ, Rodrigo Ramella; FEHER, Olavo; HOFF, Paulo M.Background: Kaposiform hemangioendothelioma (KHE) is a rare neoplasm of vascular origin that typically arises from the skin or soft tissues as a solitary tumor. The optimal therapy for this disease is still unknown. We report the case of an adult patient presenting with metastatic KHE of the spleen, who had a partial response after treatment with paclitaxel. Case Presentation: A 36-year-old man presented in November 2012 with a nontraumatic rupture of the spleen. A splenectomy was performed, and the pathology was consistent with a nonspecific vascular proliferation. Follow-up scans revealed lytic bone lesions and liver metastasis. A biopsy of the liver was performed and confirmed KHE. The decision was made to proceed with treatment with gemcitabine and docetaxel, which was discontinued due to myelotoxicity. The patient was then transferred to our institution, and a pathology review supported the diagnosis of metastatic KHE. His disease remained stable until February 2014, when he developed progression in the liver. Chemotherapy was restarted with paclitaxel, and a partial response was documented after 3 cycles. Unfortunately, disease progression occurred after 24 weeks, and subsequent treatments included prednisone, doxorubicin, interferon-a, gemcitabine, and ifosfamide, without any response. The patient developed Kasabach-Merritt phenomenon and passed away 1 week later due to a major gastrointestinal bleeding. Conclusions: This case report suggests that paclitaxel could be considered as a treatment option for advanced KHE, a rare condition for which no standard treatment exists. (C) 2016 The Author(s) Published by S. Karger AG, Basel
- Consensus of the Brazilian Society of Infectious Diseases and Brazilian Society of Clinical Oncology on the management and treatment of Kaposi's sarcoma (vol 18, pg 315, 2014)(2014) ARRUDA, Erico; JACOME, Alexandre Andrade dos Anjos; TOSCANO, Ana Luiza de Castro Conde; SILVESTRINI, Anderson Arantes; REGO, Andre Santa Barbara; WIERMANN, Evanius Garcia; CUNHA JR., Geraldo Felicio da; MELO, Heloisa Ramos Lacerda de; MOREJON, Karen Mirna Loto; GOLDANI, Luciano Zubaran; PEREIRA JR., Luiz Carlos; SILVA, Mariliza Henrique; TREISTMAN, Mauro Sergio; PEREIRA, Monica Cristina Toledo; ROMERO, Patricia Maria Bezerra Xavier; SCHMERLING, Rafael Aron; GUEDES, Rodrigo Antonio Vieira; CAMARGO, Veridiana Pires de
- Consensus of the Brazilian Society of Infectious Diseases and Brazilian Society of Clinical Oncology on the management and treatment of Kaposi's sarcoma(2014) ARRUDA, Erico; JACOME, Alexandre Andrade dos Anjos; TOSCANO, Ana Luiza de Castro Conde; SILVESTRINI, Anderson Arantes; REGO, Andre Santa Barbara; WIERMANN, Evanius Garcia; CUNHA JR., Geraldo Felicio da; MELO, Heloisa Ramos Lacerda de; MOREJON, Karen Mirna Loro; GOLDANI, Luciano Zubaran; PEREIRA JR., Luiz Carlos; SILVA, Mariliza Henrique; TREISTMAN, Mauro Sergio; PEREIRA, Monica Cristina Toledo; ROMERO, Patricia Maria Bezerra Xavier; SCHMERLING, Rafael Aron; GUEDES, Rodrigo Antonio Vieira; CAMARGO, Veridiana Pires deKaposi's sarcoma is a multifocal vascular lesion of low-grade potential that is most often present in mucocutaneous sites and usually also affects lymph nodes and visceral organs. The condition may manifest through purplish lesions, flat or raised with an irregular shape, gastrointestinal bleeding due to lesions located in the digestive system, and dyspnea and hemoptysis associated with pulmonary lesions. In the early 1980s, the appearance of several cases of Kaposi's sarcoma in homosexual men was the first alarm about a newly identified epidemic, acquired immunodeficiency syndrome. In 1994, it was finally demonstrated that the presence of a herpes virus associated with Kaposi's sarcoma called HHV-8 or Kaposi's sarcoma herpes virus and its genetic sequence was rapidly deciphered. The prevalence of this virus is very high (about 50%) in some African populations, but stands between 2% and 8% for the entire world population. Kaposi's sarcoma only develops when the immune system is depressed, as in acquired immunodeficiency syndrome, which appears to be associated with a specific variant of the Kaposi's sarcoma herpes virus. There are no treatment guidelines for Kaposi's sarcoma established in Brazil, and thus the Brazilian Society of Clinical Oncology and the Brazilian Society of Infectious Diseases developed the treatment consensus presented here.
bookPart Câncer de pele(2015) EXMAN, Pedro; OLIVEIRA, Sarah; MAK, Milena Perez; CAMARGO, Veridiana Pires debookPart Sarcomas de partes ósseas(2013) CAMARGO, Veridiana Pires de; CAMARGO, Olavo Pires de